Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

RYTM | Rhythm Pharmaceuticals, Inc.

IndexRUT P/E- EPS (ttm)-3.29 Insider Own0.10% Shs Outstand56.87M Perf Week-5.80%
Market Cap1.31B Forward P/E- EPS next Y-2.29 Insider Trans-27.15% Shs Float56.66M Perf Month-8.33%
Income-182.20M PEG- EPS next Q-0.75 Inst Own108.16% Short Float / Ratio18.80% / 13.10 Perf Quarter23.43%
Sales43.80M P/S29.82 EPS this Y-147.60% Inst Trans29.07% Short Interest10.65M Perf Half Y37.62%
Book/sh3.21 P/B7.24 EPS next Y29.30% ROA-51.10% Target Price38.22 Perf Year-3.53%
Cash/sh4.51 P/C5.15 EPS next 5Y-9.00% ROE-76.90% 52W Range15.50 - 34.99 Perf YTD-20.23%
Dividend- P/FCF- EPS past 5Y-4.20% ROI-52.70% 52W High-33.61% Beta1.63
Dividend %- Quick Ratio6.00 Sales past 5Y- Gross Margin88.20% 52W Low49.87% ATR1.17
Employees177 Current Ratio6.20 Sales Q/Q111.00% Oper. Margin- RSI (14)40.90 Volatility4.72% 4.79%
OptionableYes Debt/Eq0.43 EPS Q/Q8.00% Profit Margin- Rel Volume0.77 Prev Close24.03
ShortableYes LT Debt/Eq0.43 EarningsAug 01 BMO Payout- Avg Volume812.89K Price23.23
Recom1.70 SMA20-8.58% SMA500.88% SMA2003.41% Volume626,122 Change-3.33%
Date Action Analyst Rating Change Price Target Change
Aug-01-23Upgrade BofA Securities Neutral → Buy $22 → $27
Jan-18-23Resumed Canaccord Genuity Buy $52
Aug-08-22Upgrade Goldman Neutral → Buy $28
Aug-05-22Upgrade BofA Securities Underperform → Neutral $8 → $20
Jun-17-22Reiterated Needham Buy $40 → $25
Mar-02-22Resumed Stifel Buy $23
Feb-17-22Upgrade Ladenburg Thalmann Neutral → Buy $15
Dec-08-21Initiated Wells Fargo Overweight $30
Nov-19-21Downgrade Morgan Stanley Overweight → Equal-Weight $50 → $15
Sep-14-21Resumed Goldman Neutral $14
Sep-19-23 08:01AM
Sep-08-23 05:01PM
Sep-06-23 07:59AM
08:00AM Loading…
Aug-28-23 08:00AM
Aug-07-23 08:00AM
Aug-04-23 04:01PM
Aug-03-23 06:07AM
Aug-01-23 08:35AM
Jul-19-23 08:00AM
Jul-18-23 08:00AM
Jul-17-23 06:00AM
Jul-14-23 04:40PM
04:01PM Loading…
Jul-13-23 04:01PM
Jun-29-23 12:45PM
Jun-17-23 02:01PM
Jun-07-23 08:00AM
Jun-06-23 04:01PM
Jun-05-23 08:46AM
May-22-23 08:00AM
May-09-23 08:11AM
May-08-23 08:00AM
May-05-23 04:01PM
May-04-23 10:05AM
May-02-23 08:45AM
Apr-26-23 10:02AM
Apr-25-23 10:01AM
07:00AM Loading…
Apr-24-23 07:00AM
Apr-18-23 08:00AM
Apr-12-23 07:23AM
Apr-10-23 08:00AM
Apr-06-23 04:01PM
Mar-27-23 08:00AM
Mar-08-23 10:02PM
Mar-06-23 04:01PM
Mar-02-23 09:20PM
Mar-01-23 08:25AM
Feb-27-23 08:45AM
Feb-21-23 08:00AM
Feb-08-23 08:00AM
Jan-23-23 08:00AM
Jan-09-23 08:45AM
Jan-05-23 04:01PM
Dec-30-22 12:46AM
Dec-28-22 11:58PM
Dec-14-22 06:23AM
Dec-07-22 04:01PM
Dec-01-22 08:00AM
Nov-21-22 08:00AM
Nov-11-22 09:32AM
Nov-10-22 09:02AM
Nov-08-22 08:25AM
Nov-07-22 04:01PM
Nov-03-22 08:00AM
Nov-02-22 07:30AM
Nov-01-22 08:00AM
Oct-25-22 10:02AM
Oct-18-22 10:21AM
Oct-12-22 08:00AM
Oct-06-22 04:02PM
Sep-23-22 08:00AM
Sep-19-22 04:01PM
Sep-14-22 10:20PM
Sep-07-22 04:01PM
Sep-06-22 04:01PM
Sep-01-22 08:00AM
Aug-28-22 09:29AM
Aug-12-22 09:55AM
Aug-08-22 04:01PM
Aug-03-22 08:00AM
Aug-02-22 03:51PM
Jul-28-22 08:00AM
Jul-27-22 10:01AM
Jul-26-22 10:01AM
Jul-22-22 08:39AM
Jul-21-22 04:03PM
Jul-20-22 08:00AM
Jul-18-22 06:00AM
Jul-13-22 12:15PM
Jul-12-22 09:12AM
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alstrom syndrome. It is also developing setmelanotide, which is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lee Jennifer KaydenEVP, Head of North AmericaSep 05Option Exercise6.804,51930,7297,813Sep 07 05:48 PM
Lee Jennifer KaydenEVP, Head of North AmericaSep 05Sale28.056,166172,9581,647Sep 07 05:48 PM
Lee Jennifer KaydenEVP, Head of North AmericaAug 09Option Exercise6.801,71811,6825,012Aug 09 04:30 PM
Lee Jennifer KaydenEVP, Head of North AmericaAug 09Sale24.661,71842,3663,294Aug 09 04:30 PM
Lee Jennifer KaydenEVP, Head of North AmericaAug 07Option Exercise6.808,59158,41914,517Aug 09 04:30 PM
Lee Jennifer KaydenEVP, Head of North AmericaAug 07Sale24.1811,223271,3473,294Aug 09 04:30 PM
Cramer Pamela J.Chief Human Resources OfficerJul 26Sale17.6493016,4058,418Jul 28 09:01 PM
Smith Hunter CChief Financial OfficerJun 16Option Exercise6.882,00013,76061,406Jun 21 04:05 PM
Roberts William T.Chief Accounting OfficerMar 29Sale17.5091215,9607,872Mar 31 09:38 PM
Mazabraud YannEVP, Head of InternationalFeb 14Sale27.031,17731,8143,827Feb 16 04:05 PM
Smith Hunter CChief Financial OfficerFeb 14Sale26.8770218,86359,406Feb 14 08:59 PM
Chien JenniferEVP, Head of North AmericaFeb 14Sale26.8763517,0624,940Feb 14 08:59 PM
Shulman JosephChief Technical OfficerFeb 14Sale26.8755414,8863,741Feb 14 09:00 PM
Mazabraud YannEVP, Head of InternationalFeb 09Sale27.661,54842,8182,988Feb 13 05:03 PM
Smith Hunter CChief Financial OfficerFeb 09Sale27.661,39838,66957,779Feb 13 05:03 PM
Chien JenniferEVP, Head of North AmericaFeb 09Sale27.661,19232,9713,556Feb 13 05:04 PM
Roberts William T.Chief Accounting OfficerFeb 09Sale27.6695926,5266,294Feb 13 05:02 PM
Shulman JosephChief Technical OfficerFeb 09Sale27.6692125,4752,742Feb 13 05:00 PM
Cramer Pamela J.Chief Human Resources OfficerFeb 09Sale27.6683423,0686,151Feb 13 05:02 PM